Core Viewpoint - Pfizer has experienced significant stock price declines since its peak in late 2021, primarily due to reduced sales of its COVID-19 treatments and vaccines, but it still holds potential for future growth, particularly in oncology and offers an attractive dividend yield [2][4][5] Group 1: Stock Performance - Pfizer's stock has seen over a 60% decline from its late-2021 high, with a $10,000 investment from 10 years ago now worth just over $7,000 [2] - Including reinvested dividends, the investment would be worth approximately $10,600 over the same period, although this still lags behind broader market returns [3] Group 2: Sales and Market Reaction - The decline in stock value is largely attributed to slowing sales of its COVID-19 treatment Paxlovid and vaccine Comirnaty, with no compensating growth from other products in its portfolio [4] Group 3: Future Outlook - Despite recent setbacks, there are new growth prospects for Pfizer, especially in oncology, and the stock's forward-looking dividend yield of 7.5% may attract new investors confident in the company's future [5]
If You'd Invested $10,000 in Pfizer Stock 10 Years Ago, Here's How Much You'd Have Today